S
Santhana G. T. Devaraj
Researcher at Houston Methodist Hospital
Publications - 20
Citations - 1563
Santhana G. T. Devaraj is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Panobinostat & Histone deacetylase inhibitor. The author has an hindex of 10, co-authored 20 publications receiving 1376 citations. Previous affiliations of Santhana G. T. Devaraj include University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus *
Santhana G. T. Devaraj,Nan Wang,Zhongbin Chen,Zihong Chen,Monica Tseng,Naina Barretto,Rongtuan Lin,Clarence J. Peters,Chien Te K. Tseng,Susan C. Baker,Kui Li +10 more
TL;DR: It is shown here that infection of SARS-CoV triggers a weak IFN response in cultured human lung/bronchial epithelial cells without inducing the phosphorylation of IFN-regulatory factor 3 (IRF-3), a latent cellular transcription factor that is pivotal for type I IFN synthesis.
Journal ArticleDOI
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
Warren Fiskus,Sunil Sharma,Bhavin Shah,Bryce P. Portier,Santhana G. T. Devaraj,Ka Liu,Swaminathan P. Iyer,David J. Bearss,Kapil N. Bhalla +8 more
TL;DR: The combination of LSD1 antagonist and pan-HDI is a promising therapy warranting further testing against AML, and co-treatment with SP2509 and PS significantly improved the survival of the mice engrafted with the human AML cells, without exhibiting any toxicity.
Journal ArticleDOI
Toll-Like Receptor 3 Mediates Establishment of an Antiviral State against Hepatitis C Virus in Hepatoma Cells
TL;DR: It is shown that primary human hepatocytes express TLR3 and robustly upregulate ISGs upon poly(I·C) stimulation and thatTLR3 senses hepatitis C virus (HCV) infection when expressed in permissive hepatoma cells, acting independently of retinoic acid-inducible gene I and inducing IRF-3 activation and the synthesis of ISGs that restrict virus replication.
Journal ArticleDOI
Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Warren Fiskus,Sunil Sharma,Jun Qi,John A Valenta,Leasha J. Schaub,Bhavin Shah,Karissa Peth,Bryce P. Portier,Melissa Rodriguez,Santhana G. T. Devaraj,Ming Zhan,Jianting Sheng,Swaminathan P. Iyer,James E. Bradner,Kapil N. Bhalla +14 more
TL;DR: The sensitizing effects of the histone hyperacetylation-inducing pan–histone deacetylase (HDAC) inhibitor panobinostat on human acute myelogenous leukemia (AML) blast progenitor cells (BPC) to the BET protein antagonist JQ1 are demonstrated.
Journal ArticleDOI
Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Kyungsoo Ha,Warren Fiskus,Dong Soon Choi,Srividya Bhaskara,Leandro Cerchietti,Santhana G. T. Devaraj,Bhavin Shah,Sunil Sharma,Jenny C. Chang,Ari Melnick,Scott W. Hiebert,Kapil N. Bhalla +11 more
TL;DR: Findings presented here demonstrate that by attenuating the levels of DNA damage response and homologous recombination proteins, pan-histone deacetylase inhibitor (HDI) treatment induces ‘BRCAness’ and sensitizes TNBC cells lacking BRCA1 to lethal effects of PARP inhibitor or cisplatin.